📣 أمل جديد لمرضى الكبد الوبائي "بي": دواء مبتكر يمهد الطريق لشفاء تام!

لكل متابعينا المهتمين بالصحة والابتكارات الطبية، يسعدنا أن نشارككم خبراً ساراً يُشكل ثورة حقيقية في عالم الطب، وتحديداً في علاج التهاب الكبد الوبائي المزمن (فيروس B). أعلنت الأبحاث الطبية الحديثة عن نتائج تاريخية لجيل جديد من الأدوية يُدعى "بيبيروفيرسين" (Bepirovirsen)، والذي طورته شركتا GSK و Ionis Pharmaceuticals. هذا الدواء لا يكتفي بمجرد تثبيط الفيروس كالعلاجات التقليدية، بل يسعى لتحقيق ما يُعرف بـ "الشفاء الوظيفي" (Functional Cure). 💡 كيف يعمل هذا الدواء؟ (آلية العمل الثلاثية) يعمل "بيبيروفيرسين" بتقنية جينية متطورة كحقنة أسبوعية تحت الجلد، ويحارب الفيروس بـ 3 طرق متزامنة: تدمير الشفرة الوراثية: يقوم باستهداف الحمض النووي الريبي (RNA) للفيروس وتفتيته لمنعه من التكاثر. تصفية البروتينات: يمنع الفيروس من إنتاج بروتينات السطح (HBsAg) التي يتخفى وراءها. تحفيز المناعة: يقوم بإعادة تنشيط الجهاز المناعي للمريض، ليصبح قادراً على التعرف على الخلايا المصابة وتدميرها ذاتياً. 📊 ماذا تقول نتائج التجارب السريرية الأخيرة (Phase 3)؟ أظهرت البيانات المنشورة في "المجلة الطبية لنيو إنجلاند" (NEJM) نتائج غير مسبوقة على أكثر من 1800 مريض: نجح الدواء في تحقيق شفاء وظيفي تام بنسبة تصل إلى 20% من المرضى بعد كورس علاجي استمر لـ 24 أسبوعاً فقط (حيث اختفى الفيروس تماماً من الدم وبدون الحاجة لجرعات إضافية). ارتفعت نسبة الشفاء إلى 26% لدى المرضى الذين بدؤوا العلاج بنسب منخفضة من الفيروس في الدم. 🩺 الأمان والأعراض الجانبية أظهر الدواء معدلات أمان جيدة؛ واقتصرت معظم الأعراض الجانبية على ردود فعل خفيفة في موضع الحقن (مثل الاحمرار أو الألم الموضعي)، بالإضافة إلى بعض الإجهاد المؤقت، وارتفاع مؤقت في إنزيمات الكبد، وهو أمر يراه الأطباء إيجابياً لأنه يشير إلى أن المناعة بدأت تهاجم الخلايا المصابة بالفعل لتنظيف الكبد. ⏳ متى سيتوفر في الأسواق؟ الدواء يخضع حالياً لمراجعات سريعة وأولوية قصوى من قِبل هيئة الغذاء والدواء الأمريكية (FDA) ووكالة الأدوية الأوروبية (EMA)، ومن المتوقع صدور قرارات الاعتماد الرسمية والدخول للأسواق العالمية في أواخر عام 2026. شاركونا آرائكم واستفساراتكم في التعليقات! هل تودون معرفة الفرق بين "الشفاء الوظيفي" والشفاء النهائي؟ أو الشروط التي يجب توافرها في المريض لتلقي هذا العلاج؟ 👇 #صحة #طب #الكبد_الوبائي #فيروس_بي #ابتكار_طبي #علاج_جديد #مدونة_الصحة #توعية_طبية #Bepirovirsen  فوراً! Bepirovirsen in Chronic Hepatitis B Infection | New England ... Bepirovirsen Meets Functional Cure Endpoint in Chronic ... New Age for Hepatitis B Therapies | gutsandgrowth Sequential Peg-IFN after bepirovirsen may reduce post ... Bepirovirsen is an investigational triple-action antisense oligonucleotide (ASO) being developed by GSK and Ionis Pharmaceuticals that serves as a potential "functional cure" for chronic hepatitis B virus (HBV) infections. Unlike standard oral antiviral therapies that require lifelong adherence to suppress replication, a weekly subcutaneous injection of bepirovirsen targets viral RNA to halt protein production, clearing the virus over the long term so that the body's own immune system can regain control without ongoing medication. GSK +5 🔬 Mechanism of Action Bepirovirsen works via three unique, coordinated pathways to attack the virus: RNA Destruction: It recognizes and binds to viral genetic components (specifically mRNA and pregenomic RNA) to trigger their breakdown. GSK +1 Antigen Suppression: It dramatically reduces the production of viral proteins, significantly clearing Hepatitis B surface antigen (HBsAg) levels in the bloodstream. GSK +1 Immune Reinvigoration: It features innate immunostimulatory properties that stimulate immune effector cells, helping the body naturally kill infected liver cells. The New England Journal of Medicine +2 📊 Clinical Trial Success (Phase 3 Results) On 28 May 2026, landmark data from two replicate Phase 3 trials—B-Well 1 and B-Well 2—were published in the New England Journal of Medicine: National Institutes of Health (.gov) +2 Functional Cure Rate: Approximately 19% to 20% of patients achieved a functional cure (defined as maintaining undetectable HBsAg and HBV DNA for 24 weeks after completing the 24-week treatment course). Placebo Comparison: 0% of patients in the placebo group achieved a functional cure. Key Baseline Factors: The drug is most effective in patients with a lower baseline viral load (HBsAg levels of 3000 IU/mL or less). GSK +3 ⚠️ Side Effects & Tolerability The drug has displayed an acceptable and manageable safety profile across trials. The most common adverse events include: AJMC +1 Injection site reactions (erythema, swelling, or pain). Pyrexia (fever) and general fatigue. Transient ALT elevation: Temporary spikes in liver enzymes occur frequently. Researchers note this usually reflects a healthy therapeutic response as the immune system clears infected liver cells. National Institutes of Health (.gov) +2 🕒 Regulatory Status and Timeline: Bepirovirsen is currently under accelerated regulatory review worldwide. United States: The FDA has accepted the application under Breakthrough Therapy and Fast Track designations. The PDUFA target decision date is set for 26 October 2026. GSK +2 Europe & Global: The European Medicines Agency (EMA) accepted the drug for review in early 2026. It has also received priority review designations in China and Japan. GSK +3 If you want to dive deeper into this medical breakthrough, let me know if you would like to explore: The difference between a functional cure and a sterilizing cure. The specific patient inclusion criteria used during the B-Well trials. How this drug interacts with current standard nucleos(t)ide analogue (NA) therapies. AJMC +4 This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more 18 sites Bepirovirsen for Chronic Hepatitis B Receives Breakthrough ... M5 May 2026— The drug is an investigational antisense oligonucleotide and would be the first therapy to achieve clinically meaningful functiona... AJMC Phase 3 Results of Bepirovirsen Treatment for Chronic ... Ma29 May 2026. In addition to demonstrating the benefits of HBsAg loss, a functional cure eliminates the need for further NA treatment, thereby removing th... The New England Journal of Medicine Immunomodulation by bepirovirsen may induce killing of infected ... Oct3 October 2025Abstract * Background: Bepirovirsen is an investigational drug; its multimodal mechanism of action (MoA) is under evaluation. Obse... National Institutes of Health (.gov) Show all bepirovirsen Bepirovirsen is an investigational antisense oligonucleotide (ASO) developed by GSK and Ionis Pharmaceuticals, designed to act as a finite-duration functional cure for adults living with chronic hepatitis B virus (HBV) infection. BioPharma Dive +1 By targeting and destroying viral genetic material, the weekly subcutaneous injection suppresses viral proteins. It stimulates the patient's own immune system to regain long-term control of the virus without the need for lifelong antiviral medication. GSK +1 🔬 Mechanism of Action Bepirovirsen utilizes a distinct triple-action pathway to clear the virus: RNA Targeting: It selectively binds to all HBV genetic components (mRNA and pregenomic RNA) to trigger their destruction. Antigen Reduction: It dramatically drops the production of the Hepatitis B surface antigen (HBsAg) in the bloodstream. Immune Reinvigoration: Its chemical backbone stimulates innate immune effector cells, helping the body recognize and naturally clear infected liver cells. National Institutes of Health (.gov) +4 📊 Landmark Phase 3 Clinical Results Pivotal data from two large-scale replicate Phase 3 trials (B-Well 1 and B-Well 2) involving over 1,800 participants across 29 countries were published in the New England Journal of Medicine: Clinical Trial / Group Functional Cure Rate (at Week 72) Placebo Control Rate B-Well 1 (650 patients) 20% 0% (out of 328) B-Well 2 (570 patients) 19% 0% (out of 286) Lower Viral Baseline Subgroup (HBsAg 1000 IU/mL) 26% 0% Note: Functional cure is defined as maintaining undetectable levels of HBsAg and HBV DNA for 24 weeks after finishing the 24-week treatment course. National Institutes of Health (.gov) ⚠️ Safety and Tolerability Profile The trials showed an acceptable safety profile consistent with earlier clinical phases: HCPLive +1 Common Reactions: Most side effects were mild, led by injection-site reactions (redness, pain), fatigue, and pyrexia (fever). Liver Enzyme Spikes: Grade 3 elevations in alanine aminotransferase (ALT) occurred in 6% of patients. This is expected, as transient spikes in enzyme levels often indicate that the immune system is actively killing infected liver cells. GSK +2 🕒 Regulatory Status and Timeline Bepirovirsen is currently moving through accelerated global regulatory reviews: GSK United States: The Food and Drug Administration (FDA) accepted the drug's New Drug Application (NDA) under Breakthrough Therapy and Fast Track designations. The PDUFA target decision date is set for 26 October 2026. BioPharma Dive +1 Global Access: The drug is undergoing priority reviews with the European Medicines Agency (EMA), China's NMPA (with Breakthrough status), and Japan's MHLW under the SENKU designation. Ionis Pharmaceuticals, Inc. If you want to look more closely at this therapy, tell me if you want to explore the difference between a functional cure and a sterilizing cure. The specific patient inclusion criteria used in the B-Well trials. How this drug interacts with current standard oral nucleoside (t)ide analog (NA) therapies. National Institutes of Health (.gov) +4 This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more 13 sites Making Sense of the Antisense Therapy for Hepatitis B - PMC Bepirovirsen is a 2′-O-methoxyethyl modified antisense oligonucleotide (ASO) in development for treating chronic hepatitis B virus... National Institutes of Health (.gov) Phase 3 Results of Bepirovirsen Treatment for Chronic ...29 May 20266 — In addition to demonstrating the benefits of HBsAg loss, a functional cure eliminates the need for further NA treatment, thereby removing th... The New England Journal of Medicine Ionis partner GSK announces bepirovirsen accepted for ... 11 May 2026 — Functional cure rates were significantly higher with bepirovirsen plus standard of care compared to standard of care alone across ... Ionis Pharmaceuticals, Inc

• علاج فيروس بي الجديد 2026 (New Hepatitis B cure 2026)
• دواء بيبيروفيرسين (Bepirovirsen drug)
• الشفاء الوظيفي من فيروس B (Functional cure for HBV)
• حقن بيبيروفيرسين للكبد (Bepirovirsen injections for liver)
• أحدث علاج لالتهاب الكبد الوبائي (Latest treatment for Hepatitis B)
• أدوية شركة GSK للكبد (GSK liver medications)
• • أخبار طبية (Medical News)
  • أمراض الكبد (Liver Diseases)
  • ابتكارات علاجية (Therapeutic Innovations)
  • صحة عامة (Public Health)